The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | Is an early diagnosis of CLL beneficial in its treatment?
Richard Houlston, MD, PhD, from Institute of Cancer Research, London, UK, provides an insight as to why there is little need for concern for young people who may have chronic lymphocytic leukemia (CLL). He notes that there is little evidence suggesting that early diagnosis of the disease will lead to any change in how well the disease can be treated and states that we are currently in the infancy period of understanding how CLL is initiated and developed. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
